Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular - Scorecard - MDSpire

Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

  • By

  • Steven E. Nissen

  • Kathy Wolski

  • David D’Alessio

  • Govinda Weerakkody

  • Jacek Kiljanski

  • Russell J. Wiese

  • Imre Pavo

  • Bertrand Cariou

  • Stephen J. Nicholls

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Comparative Analysis of Cardiorenal Effects of Tirzepatide and Dulaglutide in Diabetic Patients with Cardiovascular Conditions

At a Glance

CategoryDetail
Condition
Key MechanismsRevise to include only mechanisms directly supported by the source.
Target Population
Care Setting

Key Highlights

  • highlight_1

Guideline-Based Recommendations

Diagnosis

    Management

    • R
    • e
    • m
    • o
    • v
    • e
    • u
    • n
    • s
    • u
    • p
    • p
    • o
    • r
    • t
    • e
    • d
    • m
    • a
    • n
    • a
    • g
    • e
    • m
    • e
    • n
    • t
    • r
    • e
    • c
    • o
    • m
    • m
    • e
    • n
    • d
    • a
    • t
    • i
    • o
    • n
    • s
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Add source for dose escalation information.

        Clinical Best Practices

        • best_practice_1

        Related Resources & Content

        Original Source(s)

        Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular

        • by Steven E. Nissen, Kathy Wolski, David D’Alessio, Govinda Weerakkody, Jacek Kiljanski, Russell J. Wiese, Imre Pavo, Bertrand Cariou, Stephen J. Nicholls

        • June 1, 2026

        Related Content

        The pathophysiological role of MiRNAs in heart failure

        Immune-Inflammatory markers and heart failure incidence and mortality: a population-based longitudinal study

        ChatGPT response consistency to the 2025 ESC/EACTS guidelines for the management of valvular heart disease: A test–retest study using binary and multiple-choice questions